Dose regimen of favipiravir for Ebola virus disease

The Lancet Infectious Diseases

Volumn 15, Issue 2, 2015, Pages 150-151

  Mentré, France ^a,b   Taburet, Anne Marie ^c,d,e   Guedj, Jeremie ^a,b   Anglaret, Xavier ^d   Keïta, Sakoba ^f   de Lamballerie, Xavier ^g   Malvy, Denis ^d  

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICÊTRE HOSPITAL   (France)

^d INSERM   (France)

^e DHU Hepatinov   (France)

^f National Neglected Tropical Diseases Control Program   (Guinea)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG PROTEIN BINDING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; INFLUENZA; LETTER; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; STEADY STATE; SURVIVAL; VIRAL CLEARANCE; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; HEMORRHAGIC FEVER, EBOLA; PLASMA;

ADULT; AMIDES; ANIMALS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MICE; MODELS, ANIMAL; PLASMA; PYRAZINES;

EID: 84921033572     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71047-3     Document Type: Letter

References (4)

1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013, 100:446-454.
2. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014, 104:153-155.
3. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014, 105:17-21.
4. Ksiazek T, Rollin P, Williams A, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999, 179:S177-S187.